Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 23, 2011

PPD to Act as Primary Service Provider for Elan’s Development Pipeline

  • Elan and contract research organization PPD have forged a global business collaboration establishing the latter as Elan’s primary service provider for the development of its pipeline. Elan will retain ownership of all its assets and control over each program, and will leverage PPD’s capabilities in areas spanning project and data management, biostatistics, regulatory, clinical and medical monitoring, quality assurance, and pharmacovigilance.  

    “Establishing this strategic collaboration wtih PPD will enable Elan to accelerate the progression of our science into the clinical development setting in a rapid and global fashion,” notes Eliseo Salinas, Elan’s CMO, executive vp and head of development. “The ability to fluidly access additional expertise and execution capability on a global scale will complement our internal talent and may enable us to move multiple programs forward in a parallel manner.”

    PPD is a global CRO providing drug discovery, development, and lifecycle management services. The firm has offices in 43 countries.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »